Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $230 from $225 and keeps an Overweight rating on the shares. The company’s “solid beat/raise” quarter underscores the momentum across its business, the analyst tells investors in a research note. Barclays thinks Quest’s estimates are skewed to the upside for the rest of the year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics Lifts Outlook On Strong Earnings Call
- Quest Diagnostics price target raised to $225 from $210 at Evercore ISI
- Quest Diagnostics price target raised to $225 from $220 at Jefferies
- Midday Fly By: Apple names new CEO, Amazon ups investment in Anthropic
- Early notable gainers among liquid option names on April 21st